This Frost & Sullivan research service titled U.S. Asthma/COPD Market provides an overview of the medication used to treat asthma and COPD and provides forecasts for the patient population and market revenues, along with a complete analysis of key market drivers, restraints, and challenges that are impacting this market. In this research, Frost & Sullivan's expert analysts thoroughly examine bronchodilators, anti-inflammatories, and combination therapies.
This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Services program. With this program, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
Pharmaceuticals
Respiratory
Biotechnology
COPD
Asthma
Technologies
The following technologies are covered in this research:
Bronchodilators
Anti-inflammatories
Combination therapies
Market Overview
Growth Expected in the U.S. Asthma/Chronic Obstructive Pulmonary Disease Market
The number of patients diagnosed with either asthma or chronic obstructive pulmonary disease (COPD) is expected to continue to increase in the United States. In addition, increased awareness about these diseases and more screenings will contribute to the expansion of the patient population. "The total patient population for asthma and COPD is growing," notes the analyst of this research service. "The escalation in the patient population and the development of innovative new products that address unmet needs is expected to drive growth in this market and create opportunity for revenue expansion."
Increased Awareness Vital for Improved Rates of Diagnosis
One of the major obstacles facing the U.S. asthma and COPD market is the low level of awareness about the early symptoms of both asthma and COPD. Patients with mild forms of these diseases often go undiagnosed and untreated. "Knowledge about early symptoms and the importance of proper disease management are relatively inadequate," notes the analyst of this research service. "Furthermore, this lack of awareness can lead to low diagnosis rates, poor disease control, and increase in emergency care."
(0 items)
